|Bid||1,380.20 x 0|
|Ask||1,380.60 x 0|
|Day's range||1,360.86 - 1,384.00|
|52-week range||1,284.00 - 1,847.00|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||10.93|
|Earnings date||03 Feb 2021|
|Forward dividend & yield||0.76 (5.57%)|
|Ex-dividend date||12 Nov 2020|
|1y target est||1,644.50|
The falling GlaxoSmithKline share price makes today's valuation look attractive, and the generous 5.86% yield is also tempting. So what's my problem? The post Should I ignore the falling GlaxoSmithKline share price and pocket its 6% yield anyway? appeared first on The Motley Fool UK.
Glaxo (GSK) and J&J's (JNJ)get FDA approval for Cabenuva, a once-monthly injectable regimen of cabotegravir and rilpivirine, for the treatment of adults with virally suppressed HIV-1 infection.
Merck (MRK), Glaxo (GSK), AstraZeneca (AZN) and J&J (JNJ) announce FDA approvals.